This had not been done previously, and it proved effective against some of the most challenging targets in cancer biology.” In the study, Gianneschi’s team developed PLPs that selectively bind MYC and ...
Preclinical studies have highlighted how (E,E)-bisantrene silences c-MYC gene expression via G4-DNA binding and stabilization leading to clinically relevant and broad anticancer activity ...
Pancreatic cancer is one of the deadliest cancers worldwide, with a five-year survival rate of 13%. The poor prognosis is due in part both to late detection and the cancer’s capacity to adapt and ...
Findings from a preclinical study led by VHIO’s Models of Cancer Therapies Group directed by Laura Soucek, an ICREA Research Professor and co-Founder and CSO of the VHIO and ICREA spin-off company ...
Efforts to develop effective therapies for MYC-amplified Group 3 medulloblastoma (G3-MB) are hindered by an incomplete understanding of how MYC expression is controlled in these tumors. MYC, an ...
Pancreatic cancer may evade the immune system using a clever molecular trick. Researchers found that the cancer-driving protein MYC also suppresses immune alarm signals, allowing tumors to grow ...
Cancer cells are characterized by their aggressiveness: they grow rapidly and spread to other parts of the body. To enable this, numerous mechanisms come into play, and one of them involves a protein ...
Our immune systems are remarkably adept at sounding the alarm when something goes wrong—sometimes even to the point of overreacting. But what happens when a notorious oncoprotein like MYC learns to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results